BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
1. A method of treating a mammal, the method comprising administering to a mammal having Sjögren's syndrome a composition comprising a BAFF blocking agent selected from the group consisting of:
(a) a soluble BAFF receptor selected from a BAFF-R:Fc fusion, a BCMA:Fc fusion, and a TACI:Fc fusion; and
(b) an antibody against a BAFF receptor selected from BAFF-R, BCMA, and TACI,
thereby reducing immunoglobulin production or B cell growth in the mammal.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the mammal is a mouse.
4. The method of claim 3 , wherein the mouse is a BAFF Tg mouse.
5. The method of claim 1 , wherein the salivary gland of the mammal is infiltrated by MZ like B cells.
6. The method of claim 1 , wherein the BAFF receptor is BAFF-R.
7. The method of claim 1 , wherein the BAFF receptor is TACI.
8. The method of claim 1 , wherein the BAFF receptor is BCMA.
9. The method of claim 6 , wherein the BAFF-R is human.
10. The method of claim 1 , wherein the soluble BAFF receptor comprises a portion of SEQ ID NO:27 that binds to BAFF.
11. The method of claim 6 , wherein the BAFF-R is murine.
12. The method of claim 1 , wherein the soluble BAFF receptor comprises a portion of SEQ ID NO:28 that binds to BAFF.
13. The method of claim 1 , further comprising detecting the level of B cell growth in the mammal.
14. The method of claim 1 , further comprising detecting the level of immunoglobulin production in the mammal.
15. The method of claim 1 , further comprising detecting the levels of B cell growth and immunoglobulin production in the mammal.
16. The method of claim 1 , further comprising detecting circulating levels of a rheumatoid factor in the mammal.
17. The method of claim 1 , further comprising detecting circulating levels of anti-DNA autoantibody in the mammal.